NCT04024436: A Study of TAS-120 in Patients With Metastatic Breast Cancer

NCT04024436
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: FGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Endocrine (Hormone) Therapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have breast cancer with FGFR2 amplification; HR+ patients must have received 1-3 prior endocrine-containing therapies & up to 2 prior chemotherapy regimens for advanced/metastatic disease; TNBC patients must have received at least 1 prior chemotherapy or immunotherapy.
Exclusions: Patients with prior treatment of FGFR inhibtor; HR+ patients with prior treatment of a CDK4/6 inhibitor; Patients with untreated unstable brain metastases- see tria for details
https://ClinicalTrials.gov/show/NCT04024436

Comments are closed.

Up ↑